C1254351||nanocomplex
C0053163||phenylboronic acid
C0013089||doxorubicin
C0027651||tumor
C3665472||chemotherapy
C0027651||tumors
C0085104||delivery systems
C0015730||feasibility
C1880106||clinical applications
C0700287||report
C0524527||formulation
C0085104||systemic delivery
C0003392||anti-cancer drug
C0013089||doxorubicin
C0013089||doxorubicin
C0053163||Phenylboronic acid
C0053163||Phenylboronic acid
C0032521||polymeric backbone
C1254351||poly(maleic anhydride)
C1254351||pPBA-DOX nanocomplexes
C0013089||doxorubicin
C0053163||PBA moiety
C0032521||pPBA
C1254351||nanocomplexes
C0053163||Phenylboronic acid
C0013089||doxorubicin
C0053163||PBA moiety
C1254351||ligand
C1254351||phenylboronic ester
C0027651||tumor
C1254351||nanocomplexes
C0242842||confocal microscopy
C1515655||in vivo
C0430876||fluorescence imaging
C0053163||Phenylboronic acid
C0005507||Ligand competition assays
C0053163||Phenylboronic acid
C0053163||Phenylboronic acid
C1254351||nanocomplexes
C1254351||nanocomplexes
C0013089||free DOX
C0003392||anti-cancer
C1515655||in vivo
C1254351||pPBA-DOX nanocomplex
C0752188||biomedical applications